Gamida Cell

Gamida Cell is pioneering a diverse approach to cellular therapy that utilizes nicotinamide (NAM) to expand multiple cell types — including stem cells and natural killer (NK) cells — while maintaining their original phenotype and potency. When applied to umbilical cord blood–derived cells in the production of our investigational omidubicel product for allogeneic stem cell transplant, NAM-enabled cells have improved clinical measures such as engraftment time and infection rate, potentially leading to better outcomes for patients. Gamida Cell has developed a reliable, scalable and GMP-compliant culture method for NAM expansion that yields highly functional NK cells. These cells have demonstrated ability to kill cancerous cells in both animal models and clinical trials, and are being developed in both unmodified and genetically engineered forms. The company received FDA approval for Omisirge (omidubicel-onlv), an allogenic cell therapy to reduce the risk of infection in blood cancer patients.

Gamida Cell has raised $416.22M in total funding across 17 rounds. The company is currently at the Acquired stage. Key investors include Highbridge Capital Management, Undisclosed Investor(s), Israel Biotech Fund.

Gamida Cell operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology, Pharmaceuticals, Healthcare, Patients.

Gamida Cell is based in Leshem St 12, Kiryat Gat, Israel. The company also has offices abroad.